SCHEMBL31419795

SCHEMBL31419795

Cc1cc(F)c2c(c1)C(=O)OC2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.34
ALOX15 P16050 2/20 0.34
TTR P02766 1/20 0.34
PIM1 P11309 2/20 0.32
NOTUM Q6P988 2/20 0.32
ELANE P08246 3/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP3A4 P08684 2/20 0.32
MAPT P10636 2/20 0.32
TSHR P16473 2/20 0.32
MAPK1 P28482 2/20 0.32
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
BRCA1 P38398 1/20 0.32
RECQL P46063 1/20 0.32
NPC1 O15118 1/20 0.31
PTP4A3 O75365 1/20 0.31
GMNN O75496 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19585826 1.00 TDP1 (0.34) TDP1ALOX15TTRPIM1NOTUM
SCHEMBL4117969 0.81 TDP1 (0.39) TDP1ALOX15PIM1ELANEMEN1
SCHEMBL30971010 0.81 TDP1 (0.39) TDP1ALOX15PIM1ELANEMEN1
SCHEMBL854628 0.79 TGM2 (0.38) TDP1ALOX15ALDH1A1TSHRMAOA
SCHEMBL30451169 0.76 TSHR (0.38) TDP1ALOX15TSHRCA1CA9
SCHEMBL26183091 0.76 TSHR (0.38) TDP1ALOX15TSHRCA1CA9
SCHEMBL18016210 0.76 NPC1 (0.37) TDP1ALOX15ALDH1A1NPC1
SCHEMBL30097985 0.73 ACHE (0.42) TDP1MEN1ALDH1A1CYP3A4MAPT
SCHEMBL127075 0.72 ALOX15 (0.39) TDP1ALOX15TTRALDH1A1TSHR
SCHEMBL125844 0.71 ALOX15 (0.37) TDP1ALOX15ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250121069-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250121069-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION CRBN, MDM2, STUB1 TDP1 3630/4885ALOX15 3906/4885TTR 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.